Fluticasone
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Fluticasone
- Molecular weight
- 444.52
- Structure (SMILES)
- C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF
- azithromycin and fluticasone
- fluticaps
- FLUTICAPS
- fluticasone
- Fluticasone
- FLUTICASONE [HSDB]
- fluticasone [INN]
- FLUTICASONE [MART.]
- FLUTICASONE [VANDF]
- Fluticasone [WHO-DD]
- Fluticasone 100 mcg
- Fluticasone 220 mcg
- Fluticasone 250 mcg
- Fluticasone 44 mcg
- fluticasone 500 mcg
- fluticasone hsdb
- fluticasone inn
- fluticasone mart
- fluticasone vandf
- fluticasone who dd
- Inhaled corticosteroid (fluticasone)
- opn 375
- OPN-375
- optinose
- OPTINOSE
And 4 more, listed on the interactive page.
- CAS registry numbers
- 90566-53-3
- ChEMBL ID
- CHEMBL1201396
- InChIKey
- MGNNYOODZCAHBA-GQKYHHCASA-N
- PubChem compound IDs
- 5311101
- RxNorm IDs (RxCUI)
- 41126
- FDA ingredient codes (UNII)
- CUT2W21N7U
- D07AC17
- R01AD08
- R03BA05
Sources for recorded values
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- fluticasone
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Primary target
- Yes
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Eosinophilic Esophagitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004232
- Subject identifier
- D057765
- Condition
- Croup
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007227
- Subject identifier
- D003440
- Condition
- Asthma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000684
- Condition identifier
- EFO_0004232
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005854
- Condition identifier
- EFO_0007227
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008521
- Condition identifier
- EFO_1001461
- Condition identifier
- HP_0002094
- Highest recorded phase
- 1
- Condition identifier
- HP_0006536
- Condition identifier
- HP_0100582
- Condition identifier
- MONDO_0004784
- Condition identifier
- MONDO_0004822
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005324
- Condition identifier
- MONDO_0005361
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006031
- Condition identifier
- MONDO_0006314
- Condition identifier
- MONDO_0007147
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009061
- Condition identifier
- MONDO_0011786
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0015265
- Event
- adrenal insufficiency
- Reports
- 139
- Reporting signal score
- 320.02
- Event
- adrenal suppression
- Reports
- 82
- Reporting signal score
- 337.896
- Event
- anosmia
- Reports
- 67
- Reporting signal score
- 154.939
- Event
- asthma
- Reports
- 1,646
- Reporting signal score
- 5,224.28
- Event
- asthma-chronic obstructive pulmonary disease overlap syndrome
- Reports
- 49
- Reporting signal score
- 240.48
- Event
- asthmatic crisis
- Reports
- 46
- Reporting signal score
- 142.391
- Event
- blood cortisol decreased
- Reports
- 46
- Reporting signal score
- 169.933
- Event
- blood count abnormal
- Reports
- 324
- Reporting signal score
- 918.159
- Event
- blood immunoglobulin e increased
- Reports
- 36
- Reporting signal score
- 92.1508
- Event
- blood test abnormal
- Reports
- 58
- Reporting signal score
- 97.2065
- Event
- breath sounds abnormal
- Reports
- 85
- Reporting signal score
- 244.373
- Event
- bronchial obstruction
- Reports
- 38
- Reporting signal score
- 116.845
- Event
- bronchial wall thickening
- Reports
- 27
- Reporting signal score
- 96.9819
- Event
- bronchiectasis
- Reports
- 135
- Reporting signal score
- 396.747
- Event
- bronchitis
- Reports
- 158
- Reporting signal score
- 148.129
- Event
- bursitis
- Reports
- 113
- Reporting signal score
- 274.076
- Event
- candida infection
- Reports
- 60
- Reporting signal score
- 91.9006
- Event
- central obesity
- Reports
- 27
- Reporting signal score
- 91.6916
- Event
- chest discomfort
- Reports
- 300
- Reporting signal score
- 375.114
- Event
- chronic obstructive pulmonary disease
- Reports
- 328
- Reporting signal score
- 699.115
- Event
- chronic sinusitis
- Reports
- 39
- Reporting signal score
- 95.1247
- Event
- coeliac disease
- Reports
- 115
- Reporting signal score
- 340.147
- Event
- condition aggravated
- Reports
- 260
- Reporting signal score
- 86.7498
- Event
- cough
- Reports
- 718
- Reporting signal score
- 907.064
- Event
- cushing's syndrome
- Reports
- 186
- Reporting signal score
- 625.47
And 65 more, listed on the interactive page.
- NCT00079937
- NCT00504062
- NCT00543686
- NCT00646009
- NCT00695604
- NCT01202084
- NCT03238482
- NCT04265105
- NCT00535366
- NCT00908362
- NCT01315249
- NCT01709903
- NCT01834885
- NCT01860066
- NCT00674050
- NCT01702701
- NCT01748162
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 74.6
- Calculated partition coefficient (ALogP)
- 3.47
- Calculated partition coefficient (XLogP)
- 3.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 30
- Molecular formula
- C22H27F3O4S
- Monoisotopic mass
- 444.15821500
- Natural product
- No
- Recorded assays
- 40
- Active assays
- 2
- Confirmatory
- Other
- Anti-Inflammatory Agents
- Bronchodilator Agents
- Dermatologic Agents
- Anti-Allergic Agents
Solubility
- Median
- 0.5
- Mean
- 0.5
- Minimum
- 0.5
- Maximum
- 0.5
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 1
- Mean
- 1
- Minimum
- 1
- Maximum
- 1
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (737)
- 2nd-line Treatment of Metastatic Colorectal Cancer
- 3D Evaluation of Postoperative Edema After Third Molar Surgery
- 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
- 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
- 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
- A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
- A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
- A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
- A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
- A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
- A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE
- A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
- A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors
- A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
- A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
- A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH
- A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
- A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor
- A Comparative Effectiveness RCT of Optimized Cessation Treatments
In development for (6)
- Asthma Phase 3
- Atopic eczema Phase 3
- Chronic obstructive pulmonary disease Phase 3
- Croup Phase 3
- Diabetes mellitus Phase 1
- Eosinophilic esophagitis Phase 3
Other linked conditions (5)
- Allergic asthma
- Allergic rhinitis
- Cystic fibrosis
- Respiratory system disorder
- Rhinitis